Bienville Capital Management’s AbbVie ABBV Stock Holding History

Bienville Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	4,203 -300	-7%	-$64.5K	0.14%	58
2026 Q1	$979K	Buy	4,503 +400	+10%	+$88.7K	0.18%	44
2025 Q4	$937K	Hold	4,103	–	–	0.15%	46
2025 Q3	$950K	Hold	4,103	–	–	0.18%	45
2025 Q2	$762K	Hold	4,103	–	–	0.15%	44
2025 Q1	$860K	Hold	4,103	–	–	0.21%	40
2024 Q4	$729K	Hold	4,103	–	–	0.18%	46
2024 Q3	$810K	Hold	4,103	–	–	0.21%	43
2024 Q2	$704K	Hold	4,103	–	–	0.17%	47
2024 Q1	$747K	Hold	4,103	–	–	0.23%	49
2023 Q4	$636K	Hold	4,103	–	–	0.17%	57
2023 Q3	$612K	Hold	4,103	–	–	0.17%	52
2023 Q2	$553K	Hold	4,103	–	–	0.19%	51
2023 Q1	$654K	Hold	4,103	–	–	0.24%	42
2022 Q4	$663K	Hold	4,103	–	–	0.2%	42
2022 Q3	$551K	Hold	4,103	–	–	0.22%	56
2022 Q2	$628K	Hold	4,103	–	–	0.3%	69
2022 Q1	$665K	Hold	4,103	–	–	0.33%	74
2021 Q4	$556K	Hold	4,103	–	–	0.4%	49
2021 Q3	$443K	Hold	4,103	–	–	0.25%	61
2021 Q2	$462K	Sell	4,103 -232	-5%	-$26.1K	0.04%	96
2021 Q1	$469K	Buy	4,335 +232	+6%	+$24.8K	0.06%	91
2020 Q4	$440K	Hold	4,103	–	–	0.04%	77
2020 Q3	$359K	Sell	4,103 -1,795	-30%	-$169K	0.04%	86
2020 Q2	$579K	Buy	5,898 +600	+11%	+$52.8K	0.05%	59
2020 Q1	$404K	Buy	5,298 +1,195	+29%	+$102K	0.08%	55
2019 Q4	$363K	Hold	4,103	–	–	0.09%	52
2019 Q3	$311K	Sell	4,103 -6,322	-61%	-$433K	0.04%	62
2019 Q2	$758K	Sell	10,425 -199	-2%	-$15.6K	0.09%	58
2019 Q1	$856K	Sell	10,624 -359	-3%	-$29.4K	0.1%	50
2018 Q4	$1.01M	Buy	10,983 +5,163	+89%	+$454K	0.2%	37
2018 Q3	$550K	Sell	5,820 -26	-0.4%	-$2.47K	0.04%	48
2018 Q2	$542K	Buy	5,846 +174	+3%	+$17K	0.04%	61
2018 Q1	$537K	Sell	5,672 -6,813	-55%	-$748K	0.08%	63
2017 Q4	$1.21M	Sell	12,485 -31	-0.2%	-$2.92K	0.21%	44
2017 Q3	$1.11M	Buy	12,516 +737	+6%	+$56.1K	0.19%	40
2017 Q2	$854K	Sell	11,779 -79	-0.7%	-$5.31K	0.24%	43
2017 Q1	$773K	Sell	11,858 -292	-2%	-$18.4K	0.18%	43
2016 Q4	$761K	Buy	12,150 +944	+8%	+$57.6K	0.17%	41
2016 Q3	$707K	Sell	11,206 -138	-1%	-$8.93K	0.18%	41
2016 Q2	$702K	Buy	11,344 +4,844	+75%	+$295K	0.19%	31
2016 Q1	$371K	Hold	6,500	–	–	0.12%	37
2015 Q4	$385K	Hold	6,500	–	–	0.14%	37
2015 Q3	$354K	Hold	6,500	–	–	0.15%	42
2015 Q2	$437K	Buy	+6,500	New	+$424K	0.18%	40
2015 Q1	–	Sell	-7,000	Closed	-$458K	–	50
2014 Q4	$458K	Buy	+7,000	New	+$441K	0.38%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bienville Capital Management's ABBV Position: Q2 2026 in Review

Bienville Capital Management reduced its AbbVie (ABBV) stake by 6.7% in Q2 2026, selling an estimated $64.5K and leaving 4,203 shares worth $1.06M. The position accounts for 0.14% of the portfolio, ranked #58.

Bienville Capital Management first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.21M in Q4 2017. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Bienville Capital Management held 4,203 shares of AbbVie worth $1.06M as of Q2 2026.
Bienville Capital Management sold 300 AbbVie shares in Q2 2026, an estimated $64.5K.
AbbVie made up 0.14% of Bienville Capital Management's portfolio in Q2 2026, its #58 holding.
Bienville Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
Bienville Capital Management's AbbVie position peaked at $1.21M in Q4 2017.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bienville Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.